DrugPatentWatch Database Preview» See Plans and Pricing
« Back to Dashboard
Summary for Patent: 8,097,252
|Title:||Methods and compositions for administering therapeutic and diagnostic agents|
|Abstract:||Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.|
|Inventor(s):||McBride; William J. (Boonton, NJ), Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), Hansen; Hans J. (Picayune, MS)|
|Assignee:||Immunomedics, Inc. (Morris Plains, NJ)|
|Patent Claims:||1. A kit comprising: a) a bispecific antibody comprising at least one target binding moiety that binds to a tumor-associated marker selected from the group consisting of
carcinoembryonic antigen (CEA), colon-specific antigen-p (CSAp), CD4, CD5, CD8, CD14, CD15, CD19, CD20, CD22, CD40, CD40L, CD74, B7, HLA-DR, EGFR, HER 2/neu, TAG-72, EGP-1, HCG, HCG-beta, PSMA, PSA, VEGF, IL-2 and MAGE and at least one first targetable
construct binding moiety that binds to a hapten selected from the group consisting of HSG (histamine succinyl glycine) and In-DTPA; b) a targetable construct comprising a first hapten that is HSG and a second hapten that is In-DTPA, wherein said
targetable construct comprises at least one therapeutic or diagnostic agent; and c) an internalization agent comprising a second targetable construct binding moiety that binds to a hapten selected from the group consisting of HSG and In-DTPA and an
internalization moiety selected from the group consisting of an anti-CD74 antigen-binding antibody fragment and a folate; wherein said first and second targetable construct binding moieties bind to different haptens and wherein binding of the
internalization agent to the second targetable construct enhances internalization of the diagnostic or therapeutic agent.
2. The kit of claim 1, wherein said target binding moiety, first targetable construct binding moiety, second targetable construct binding moiety and internalization moiety are antibody fragments selected from the group consisting of F(ab').sub.2, Fab', Fab, Fv, sFy and scFv antibody fragments.
3. The kit of claim 2, wherein said internalization moiety is an anti-CD74 antigen-binding antibody fragment.
4. The kit of claim 3, wherein said anti-CD74 antibody fragment is an LL1 antibody fragment.
5. The kit of claim 2, wherein said antibody fragment is a fragment of a humanized antibody, chimeric antibody, human antibody or murine antibody.
6. The kit of claim 1, wherein said HSG binding moiety is a 679 antibody fragment and said In-DTPA binding moiety in a) and c) is a 734 antibody fragment.
7. The kit of claim 1, wherein said therapeutic agent is selected from the group consisting of a drug, a prodrug, a toxin, an enzyme, an enzyme that activates a prodrug to a drug, an enzyme-inhibitor, a nuclease, a hormone, a hormone antagonist, an immunomodulator, a boron compound, a photoactive agent a dye and a radionuclide.
8. The kit of claim 7, wherein said therapeutic agent is selected from the group consisting of aplidin, azaribine, anastrozole, azacytidine, bleomycin, bortezomib, bryostatin-1, busulfan, camptothecin, 10-hydroxycamptothecin, carmustine, chlorambucil, cisplatin, irinotecan (CPT-11), SN-38, carboplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunomycin glucuronide, daunorubicin, dexamethasone, diethylstilbestrol, doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, ethinyl estradiol, estramustine, etoposide, etoposide glucuronide, etoposide phosphate, floxuridine (FUdR), 3',5'-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, fluorouracil, fluoxymesterone, gemcitabine, hydroxyprogesterone caproate, hydroxyurea, idarubicin, ifosfamide, L-asparaginase, leucovorin, lomustine, mechlorethamine, medroprogesterone acetate, megestrol acetate, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, phenyl butyrate, prednisone, procarbazine, paclitaxel, pentostatin, semustine streptozocin, tamoxifen, taxanes, taxol, testosterone propionate, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vinblastine, vinorelbine, vincristine, ricin, abrin, ribonuclease, rapLR1, DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtheria toxin, Pseudomonas exotoxin, Pseudomonas endotoxin, nitrogen mustard, ethyleneimine derivative, alkyl sulfonate, nitrosourea, triazene, folic acid, anthracycline, COX-2 inhibitor, pyrimidine analog, purine analog, antibiotic, epipodophyllotoxin, platinum coordination complex, vinca alkaloid, substituted urea, methyl hydrazine derivative, adrenocortical suppressant, endostatin, cytokine, interleukin, interferon, lymphokine, and tumor necrosis factor.
9. The kit of claim 7, wherein said radionuclide is selected from the group consisting of .sup.18F, .sup.32P, .sup.33P, .sup.45Ti, .sup.47Sc, .sup.52Fe, .sup.59Fe, .sup.62Cu, .sup.64Cu, .sup.67Cu, .sup.67Ga, .sup.68Ga, .sup.75Se, .sup.77As, .sup.86Y, .sup.89Zr, .sup.90Y, .sup.94Tc, .sup.94mTc, .sup.99Mo, .sup.99mTc, .sup.105Pd, .sup.105Rh, .sup.111Ag, .sup.111In, .sup.123I, .sup.124I, .sup.125I, .sup.131I, .sup.142Pr, .sup.143Pr, .sup.149Pm, .sup.153Sm, .sup.154-158Gd, .sup.161Tb, .sup.166Dy, .sup.166Ho, .sup.169Er, .sup.175Lu, .sup.177Lu, .sup.186Re, .sup.188Re, .sup.189Re, .sup.192Ir, .sup.198Au, .sup.199Au, .sup.211At, .sup.211Pb, .sup.212Bi, .sup.212Pb, .sup.213Bi, .sup.223Ra and .sup.225Ac.
10. The kit of claim 1, wherein said diagnostic agent is selected from the group consisting of a photoactive agent or dye, a radionuclide, a radio-opaque material, a contrast agent, and a fluorescent compound.
11. The kit of claim 10, wherein said radionuclide is selected from the group consisting of .sup.18F, .sup.45Ti, .sup.52Fe, .sup.62Cu, .sup.64Cu, .sup.67Cu, .sup.67Ga, .sup.90Y, .sup.99mTc, .sup.111Ag, .sup.111In, .sup.125I, .sup.131I, .sup.142Pr, .sup.153Sm, .sup.161Tb, .sup.166Dy, .sup.166Ho, .sup.177Lu, .sup.186Re, .sup.188Re, .sup.189Re, .sup.211At, .sup.212Bi, .sup.212Pb, .sup.213Bi, .sup.223Ra and .sup.225AC.
12. A kit comprising: a) a primary targeting agent comprising a first bispecific antibody that binds to a tumor-associated antigen (TAA) and to a first hapten, wherein the first hapten is selected from the group consisting of HSG (histamine-succinyl-glycine) and In-DTPA and wherein the TAA is selected from the group consisting of carcinoembryonic antigen (CEA), colon-specific antigen-p (CSAp), CD4, CD5, CD8, CD14, CD15, CD19, CD20, CD22, CD40, CD40L, CD74, B7, HLA-DR, EGFR, HER 2/neu, EGP-1, HCG, HCG-beta, PSMA, PSA, VEGF, IL-2, and MAGE; b) a targetable construct comprising at least one therapeutic or diagnostic agent, a first hapten and a second hapten, each hapten selected from the group consisting of HSG and In-DTPA, wherein the first and second haptens are different; and c) an internalization agent comprising a second bispecific antibody that binds to said second hapten and to CD74; wherein the targetable construct and the internalization agent are administered after the primary targeting agent.
13. The kit of claim 12, wherein the second bispecific antibody comprises an hLL1 antibody or antigen-binding fragment thereof.
14. The kit of claim 12, wherein the TAA is CEA, the first bispecific antibody is hMN-14.times.679, the targetable construct comprises two HSG haptens and one In-DTPA hapten and the second bispecific antibody is hLL1.times.734.
15. The kit of claim 14, wherein the second bispecific antibody comprises two copies of hLL1 and one copy of 734, or two copies of 734 and one copy of hLL1.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Merck||ELSPAR||asparaginase||VIAL||101063||001||1978-01-10||Start Trial||Immunomedics, Inc. (Morris Plains, NJ)||2023-01-31||RX||search|
|Jubilant Hollisterstier Llc||POSITIVE SKIN TEST CONTROL - HISTAMINE||histamine||INJECTION||103891||1||1995-06-15||Start Trial||Immunomedics, Inc. (Morris Plains, NJ)||2023-01-31||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Estimated Expiration|
|World Intellectual Property Organization (WIPO)||2004074434||Start Trial|
|United States of America||2004241158||Start Trial|
|United States of America||2009238757||Start Trial|
|United States of America||2011117010||Start Trial|
|United States of America||7534431||Start Trial|
|United States of America||7892547||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.